FemTech is no longer a niche category within healthcare innovation. Conditions such as menopause, endometriosis, and PCOS are gaining increasing recognition as major health concerns and areas with significant unmet market demand. PCOS alone affects an estimated 6–13% of women of reproductive age globally.
At the same time, women’s health technologies spanning diagnostics, mental health, and preventative care are attracting growing attention from founders, investors, and healthcare systems worldwide. Yet despite increasing momentum, many startups continue to face the same challenge: how do you scale meaningful innovation into sustainable healthcare businesses?
This question sat at the center of a recent expert session hosted through the QSTP × Merck FemTech Accelerator, where founders, researchers, and ecosystem experts gathered to discuss the realities shaping today’s FemTech landscape. Led by Julie Pelta, SVP of Global Sales at DataArt, Director at Nelson Advisors, and Health & Life Sciences Assessor at Innovate UK, the session explored the opportunities, bottlenecks, and operational challenges defining the next phase of women’s health innovation.
One message emerged consistently throughout the discussion: innovation alone is not enough.
Where Momentum in FemTech Is Emerging
While high-growth areas such as menopause, endometriosis, PCOS, and mental health continue to gain traction, founders are increasingly operating in an environment where commercialization strategy, partnerships, execution, and clinical validation matter just as much as the technology itself.
Your product or your service does not need to be perfect. It’s the execution of how you sell that will really differentiate your success.
Julie Pelta
The conversation highlighted a growing shift in how investors and healthcare organizations approach innovation. Rather than investing heavily in early-stage concepts alone, many are now prioritizing startups that can demonstrate market traction, operational readiness, and clear pathways to adoption.
“If you’re not trying to create a market, you need to think about market share,” Julie noted. “That’s a much easier place for you to navigate than creating your own market.”
The session also explored how acquisition readiness is increasingly shaping the FemTech ecosystem. Large healthcare organizations and strategic partners are placing greater emphasis on startups that can demonstrate sustainable growth models, commercial validation, and realistic pathways to scale.
The Founder Reality: Innovation Meets Structural Challenges
At the same time, founders participating in the breakout discussions described a more complicated reality behind the scenes, one shaped by funding pressures, regulatory complexity, commercialization uncertainty, and the ongoing challenge of translating innovation into investor confidence.
Fundraising emerged as the most frequently cited bottleneck among participating startups. Several founders spoke openly about the disconnect between investor expectations and the realities of early-stage healthcare innovation, particularly within women’s health.
“Viewing women’s health as a small specialized niche rather than a market serving nearly 50% of the global population,” said founder Adaobi Duru, describing one of the recurring misconceptions many companies continue to face when approaching investors.
Others pointed to the pressure to achieve milestones that often require the very funding founders are trying to secure.
“They want you to hit the milestone that essentially you need their money to reach there,” noted founder Mo’men Yaseen. “Their expectations are way beyond our current stage of capability and what we can achieve.”
The discussions also emphasized the importance of finding investors who bring strategic value beyond capital alone. Several participants noted that early-stage founders can sometimes feel pressured to accept funding too quickly, even when investor expectations, timelines, or long-term visions may not fully align with the realities of building healthcare companies.
Beyond fundraising, founders also highlighted the communication gap that often exists between technical teams and investors, where strong innovation alone is not always enough to clearly communicate scalability, market value, and long-term commercial potential.
“There’s a gap between us and the investors in terms of the language that we’re speaking,” said founder Shiyao Bao. “We just don’t find the right way to communicate.”
The discussion also touched on the gender dynamics that continue to shape women’s health entrepreneurship. Founder Noor Jaber reflected on the additional scrutiny many women founders still experience while building companies in healthcare and deep technology sectors.
As a woman, I feel that there isn’t enough trust in our skills and that we can actually pull a business together.
Noor Jaber
Alongside these challenges, the session reinforced the importance of partnerships, reimbursement pathways, clinical validation, and early pilots in helping startups move from promising innovation to sustainable growth. For many founders, generating validation and demonstrating real-world value early on has become just as important as product development itself.
“If you fall out of the reimbursement route, you will have a problem,” Julie explained. “The best advice I can give is to fit into what already exists. Then it becomes a much easier conversation.”
Ultimately, the session painted a nuanced picture of today’s FemTech landscape, one filled with both significant opportunity and persistent structural challenges. While innovation in women’s health continues to accelerate, scaling requires more than strong ideas alone. It requires execution, trust, partnerships, and ecosystems capable of turning meaningful innovation into lasting impact.
Join us to learn more about our accelerators and programs, and connect with a growing community creating meaningful impact through technology and science.
#QSTP #FemTech #WomensHealth #HealthTech #Innovation #Startups #Impact #Qatar